**Abstract**

**Introduction:** Treatment of psychiatric diseases during pregnancy is complicated by the concern for the safety of the unborn child because all psychotropic medications more or less cross the placenta. Fetal outcome is influenced by various factors and - among others - the effects of a specific drug itself depend on the concentration in maternal and fetal serum as well as on its concentration in amniotic fluid.

**Method:** The present study is a naturalistic prospective investigation of different psychotropic drug concentrations in maternal serum (MS) and amniotic fluid (AF) of 14 women and umbilical cord blood (UC) of nine newborns. The women were treated with different doses of psychotropic drugs such as antidepressants, antipsychotics, anticonvulsants and others.

**Results:** Patients received thirteen different psychotropic drugs. Results are available for five antidepressants (citalopram, paroxetine, sertraline, fluoxetine and venlafaxine), 3 anticonvulsants (valproic acid, levetiracetam, lamotrigine), 2 benzodiazepines (diazepam, clobazam), as well as for olanzapine, methadone and methylphenidate. Concentrations of different psychotropic drugs were found in maternal plasma, amniotic fluid an umbilical cord blood in highly variable concentrations suggesting that fetal exposure is continual and may occur through a variety of paths accounting for increased fetal exposure.

**Conclusion:** The preliminary data of this ongoing study highlight the penetration of different psychotropic drugs into the amniotic fluid as another way of fetal exposure. Of particular interest in this context is the observation that the well known teratogenic valproic acid does not accumulate in AF in approximately the same way as other anticonvulsants do, however valproic acid has the highest penetration ratio into umbilical cord blood with potentially negative effects on the offspring. Understanding the current data and their limitations will allow providers to guide their patients in choosing treatment options. Consistent and simple strategies should be used when discussing the risk-benefit analysis with the patient.
